Key Findings

🫁 Lung Cancer Patients Live Longer on GLP-1s

In a study of 1,177 overweight patients who had lung cancer surgery, those taking GLP-1 drugs had dramatically better outcomes. The recurrence-free survival improved significantly (59% lower risk), and when combined with immunotherapy in advanced cases, both overall survival (59% better) and progression-free survival (69% better) improved substantially. Mouse studies showed the drugs actually changed the tumor environment, making it more hostile to cancer growth.

👁️ Eye Inflammation Drops by Half

Analyzing 516,052 patients, researchers found that people prescribed GLP-1 drugs had 52% lower rates of uveitis (serious eye inflammation that can cause blindness). This protective effect worked equally well in people with and without diabetes. Even compared to other diabetes medications like metformin and insulin, GLP-1s offered superior protection against eye inflammation.

😴 Sleep Apnea Risk Falls by 17%

Using genetic analysis of 451,684 people, scientists found that GLP-1 receptor activation was associated with a 17% lower risk of obstructive sleep apnea. This wasn't just because of weight loss - the genetic approach suggests the drugs have direct protective effects on sleep-disordered breathing beyond their impact on body weight.

❤️ Heart and Kidney Protection Without Diabetes

In 140,169 matched pairs of obese adults without diabetes, those taking GLP-1 drugs had 24% lower rates of major heart problems, 36% lower rates of serious kidney events, and 51% lower risk of death from any cause. Mental health improved too, with 37% less depression and 42% less suicidal ideation. The average follow-up was just over a year.

🧠 Brain Cells That Control Hunger Get Shut Down Fast

Using real-time brain monitoring in mice, researchers discovered that GLP-1 and GIP (the hormones these drugs mimic) directly and rapidly shut down AgRP neurons - the brain cells that drive hunger. Interestingly, natural GIP from food was required for normal appetite control, while both hormones at drug doses could suppress appetite. Dual agonists like tirzepatide were more potent than single hormone treatments.

⚠️ Colorectal Cancer Risk May Increase

A meta-analysis of 7 studies covering over 5 million patients found a concerning 131% increased risk of colorectal cancer among GLP-1 users. However, when compared directly to other diabetes drugs rather than the general population, the increased risk wasn't statistically significant. The researchers noted this needs much longer follow-up studies to clarify the true risk.